Background Novel therapies for relapsed or refractory follicular lymphoma are commonly
evaluated in single-arm studies without formal comparison with other treatments or historical …

The SCHOLAR-5 study examines treatment patterns and outcomes of real-world follicular
lymphoma (FL) patients on 3 rd line of treatment (LoT) or higher, for whom existing data are …

This study (ReCORD-FL) sought to construct a historical control cohort to augment single-
arm trials in relapsed/refractory follicular lymphoma (r/r FL). A retrospective study in 10 …

Follicular lymphoma (FL) is the second most common lymphoma, and by virtue of its
chronicity, may be the most prevalent and most treated lymphoma in the United States …

The management of patients with relapsed or refractory follicular lymphoma has evolved
markedly in the last decade, with the availability of new classes of agents (phosphoinositide …

BACKGROUND Despite international practice guidelines endorsing radiotherapy (RT) as
the preferred initial therapy, treatment approaches vary for patients with early‐stage follicular …

Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine,
and prednisone) with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine …

Purpose: The role of the minimal residual disease (MRD) in follicular lymphoma is still
debated. In this study, we assessed whether the BCL2/IGH rearrangement could have a …

For the majority of patients with newly diagnosed follicular lymphoma (FL), current
treatments, while not curative, allow for long remission durations. However, several …

By using the GRADE system, we updated the guidelines for management of follicular cell
lymphoma issued in 2006 from SIE, SIES, and GITMO group. We confirmed our …